Ajanta Pharma share news, announcements and annual reports
NSE: AJANTPHARMBSE: 532331Pharmaceuticals & BiotechnologyMid Cap
Ajanta Pharma Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2000 on NSE, Jun 2000 on BSE
Last close ₹3,508.80up ₹49.10 (1.42%)BSE ₹3,512.40
Share price at the NSE close on 30 Oct 2026. Previous close ₹3,459.70.
30 Oct: open ₹3,479.00, high ₹3,619.90, low ₹3,460.50
52-week range of traded prices to 30 Oct 2026
₹2,430.00Low, 30 Oct 2025₹3,796.00High, 18 Aug 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹43,846 Cr236th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 34.72
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 9.02
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.71%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 30.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,52,55826.6% delivered
Ajanta Pharma board and management
19 filed, newest first.
Apr 2025
30 Apr · Management
30 Apr · Management
Jul 2024
May 2024
Apr 2019
Aug 2018
Dec 2017
15 Dec · Management
Mar 2014
Jan 2014
14 Jan · Management
EXIM Bank has vide letter dated January 10, 2014 withdrawn nomination of Ms. Madhu Verma as Director of the Company. Accordingly, Ms. Madhu Verma ceases to be Director of the Company with immediate effect.
May 2013
21 May · Management
Mr. Rajesh M. Agrawal and Mr. K H Viswanathan have been appointed as Additional Directors w.e.f. April 30, 2013.Further, Mr. Rajesh M. Agrawal is appointed as Joint Managing Director effective from May 01, 2013 subject to the approval of shareholders at the ensuing Annual General Meeting.
Sep 2011
5 Sep · Management
Ms. Madhu Verma has been appointment as Nominee Director (representing EXIM Bank) w.e.f. August 25, 2011 and Mr. Navin B. Gangawane has ceased to be the director of the company w.e.f. August 17, 2011 on account of his death.
May 2011
2 May · Management
Ms. Manjiri Bhalerao, a Nominee Director of the Company representing Export Import Bank of India has resigned w.e.f. April 30, 2011 and in her place Mr. Navin Gangawane has been appointed as the new Nominee Director of the Company representing the Export Import Bank of India w.e.f. April 30, 2011.
Aug 2009
4 Aug · Management
Nikhil Bhatt had joined as a Company Secretary in the organization w.e.f. January 22, 2009 in place of Mr. C Napoleon who had resigned from the organization on January 17, 2009.4 Aug · Management
Mr. Santosh Bhattcherjee, Nominee Director of Industrial Development Bank of India has resigned w.e.f. 30th July, 2009 and in his place Mr. Subal Chandra Saha has been appointed as a Nominee Director w.e.f. 30th July, 2009
May 2009
29 May · Management
Mr. Chandrakant Khetan has been appointed as Additional Director of the Company w.e.f. October 20, 2008 and to hold office till ensuing Annual General Meeting pursuant to the provision of Section 260 of the Companies Act, 1956 and Article No. 118 of the Articles of Association of the Company.
Aug 2008
13 Aug · Management
(1) Mr.Vikramaditya Ugra, Nominee Director of EXIM Bank has resigned w.e.f 26th July,2008 and in his place Ms.Manjiri Bhalerao has been appointed w.e.f. 28th July,2008. (2) Mr.Madhukar has resigned w.e.f 31st July,2008.
Jan 2007
12 Jan · Management
Mr. O. P. Singh, has resigned from the Secretaryship w.e.f. 31st August, 2006 and Mr. C. Napoleon has joined in his place as Company Secretary w.e.f. 20th December, 2006